Methenolone Enanthate is a mild injectable anabolic for lean muscle preservation. Known as Primobolan, it’s ideal for cutting cycles with low side effects and quality gains.
Effects on the Body
• Promotes lean muscle retention during cuts
• Enhances nitrogen retention and immune response
• Improves muscle hardness and definition
• Low estrogen and androgen sides
• Supports fat loss and strength
Recommended Dosage
Men: 400–800 mg/week
Women: 50–100 mg/week
Half-Life
Approx. 8 days
### PRIMOMED 100 (methenolone enanthate) Injection
**HIGHLIGHTS OF PRESCRIBING INFORMATION**
These highlights do not include all the information needed to use PRIMOMED 100 safely and effectively. See full prescribing information for PRIMOMED 100.
PRIMOMED 100 (methenolone enanthate) injection, for intramuscular use
**INDICATIONS AND USAGE**
PRIMOMED 100 is an anabolic steroid indicated for investigational use in promoting lean muscle preservation, fat loss, and strength in cutting cycles. Not approved for human therapeutic use in many jurisdictions; consult local regulations (1).
**DOSAGE AND ADMINISTRATION**
– Administer by deep intramuscular injection.
– Adult males: 400 mg to 800 mg per week, divided into two or three equal doses.
– Adult females: 50 mg to 100 mg per week, divided into two or three equal doses (2.1).
– Cycle duration: Typically 8 to 12 weeks.
**DOSAGE FORMS AND STRENGTHS**
Injection: 100 mg/mL in multi-dose vials (3).
**CONTRAINDICATIONS**
– Known or suspected carcinoma of the prostate or breast in males.
– Known or suspected carcinoma of the breast in females with hypercalcemia.
– Pregnancy (4).
– Hypersensitivity to methenolone enanthate, ethyl oleate, ricinus oil, or any component of the formulation (4).
**WARNINGS AND PRECAUTIONS**
– Hepatotoxicity: Monitor liver function tests (5.1).
– Cardiovascular risk: May alter lipid profiles; monitor cholesterol (5.2).
– Androgenic effects: Risk of virilization in females; discontinue if occurs (5.3).
– Suppression of endogenous testosterone: Use post-cycle therapy (5.4).
– Local reactions: Ethyl oleate or ricinus oil may cause injection site irritation (5.5).
**ADVERSE REACTIONS**
Common adverse reactions include mild acne, hair loss, and injection site pain (6).
**DRUG INTERACTIONS**
– Anticoagulants: May enhance effects; monitor prothrombin time (7.1).
– Insulin or oral hypoglycemics: May alter glucose levels; adjust doses (7.2).
**USE IN SPECIFIC POPULATIONS**
– Pregnancy: Contraindicated (8.1).
– Lactation: Not recommended (8.2).
– Pediatric use: Not recommended; risk of premature epiphyseal closure (8.4).
– Geriatric use: Increased risk of prostate issues (8.5).
Revised: 08/2025
**FULL PRESCRIBING INFORMATION**
**1 INDICATIONS AND USAGE**
PRIMOMED 100 is indicated for investigational use in adults to promote lean muscle retention, enhance nitrogen retention, boost immune function, improve muscle hardness and vascularity, support fat loss, and increase strength with minimal side effects. It is commonly used in cutting cycles for a defined physique. This product is not approved for any medical condition and should be used under medical supervision.
**2 DOSAGE AND ADMINISTRATION**
**2.1 Recommended Dosage**
Administer PRIMOMED 100 by deep intramuscular injection into the gluteal muscle or other large muscle groups. Rotate injection sites to minimize irritation.
– Males: 400 mg to 800 mg weekly, administered in divided doses (e.g., every 3-4 days).
– Females: 50 mg to 100 mg weekly, in divided doses to minimize virilization risk.
Adjust dosage based on response and tolerance. Discontinue if adverse effects occur.
**2.2 Preparation and Handling**
Inspect vial for particulate matter or discoloration before use. Use sterile technique for administration.
**3 DOSAGE FORMS AND STRENGTHS**
PRIMOMED 100 is supplied as a sterile solution containing 100 mg methenolone enanthate per mL in 10 mL multi-dose vials.
**4 CONTRAINDICATIONS**
PRIMOMED 100 is contraindicated in:
– Patients with known or suspected prostate or breast carcinoma.
– Pregnant women (Category X).
– Patients with hypersensitivity to methenolone enanthate, ethyl oleate, ricinus oil, or other excipients.
– Patients with severe cardiac, hepatic, or renal insufficiency.
**5 WARNINGS AND PRECAUTIONS**
**5.1 Hepatotoxicity**
May cause elevated liver enzymes or, rarely, peliosis hepatis. Perform liver function tests before and during therapy; discontinue if jaundice or abnormal tests occur.
**5.2 Cardiovascular Effects**
May alter serum lipid profiles, increasing LDL and decreasing HDL, raising the risk of atherosclerosis. Monitor cholesterol levels periodically during treatment.
**5.3 Androgenic Effects**
Females may experience virilization, including deepening of voice, hirsutism, or clitoromegaly, which may be irreversible. Discontinue immediately if signs of virilization appear.
**5.4 Endocrine Effects**
Suppresses hypothalamic-pituitary-gonadal axis, reducing natural testosterone production. Implement post-cycle therapy to restore hormonal balance.
**5.5 Injection Site Reactions**
Ethyl oleate and ricinus oil may cause localized pain, redness, or swelling at the injection site. Rotate injection sites and monitor for signs of infection or abscess.
**6 ADVERSE REACTIONS**
Reported adverse reactions include:
– Dermatologic: Mild acne, oily skin, male pattern baldness in predisposed individuals.
– Endocrine: Libido changes, testicular atrophy, reduced fertility in males.
– Cardiovascular: Hypertension, altered lipid profiles.
– Hepatic: Elevated AST/ALT, jaundice (rare).
– Local: Injection site pain, erythema, or abscess (rare).
**7 DRUG INTERACTIONS**
**7.1 Anticoagulants**
May increase bleeding risk with warfarin or other anticoagulants; monitor INR or prothrombin time closely.
**7.2 Hypoglycemic Agents**
May alter blood glucose levels, potentially requiring adjustment of insulin or oral antidiabetic doses; monitor closely.
**7.3 Corticosteroids**
Concurrent use may increase risk of edema, particularly in patients with cardiac or renal conditions.
**8 USE IN SPECIFIC POPULATIONS**
**8.1 Pregnancy**
Category X: May cause fetal harm, including virilization of a female fetus. Contraindicated in pregnant women.
**8.2 Lactation**
Excretion in breast milk is unknown; breastfeeding is not recommended due to potential risks to the infant.
**8.4 Pediatric Use**
Not recommended; may cause premature epiphyseal closure, leading to stunted growth.
**8.5 Geriatric Use**
Increased risk of prostatic hypertrophy or carcinoma; monitor prostate health closely during use.
**9 DRUG ABUSE AND DEPENDENCE**
Controlled substance in some jurisdictions. Potential for misuse leading to physical or psychological dependence, particularly with prolonged use or high doses.
**10 OVERDOSAGE**
Symptoms of overdose may include mild androgenic effects, such as acne or hair loss. No specific antidote exists; treat symptomatically and discontinue use immediately.
**11 DESCRIPTION**
PRIMOMED 100 contains methenolone enanthate, a mild anabolic steroid derived from dihydrotestosterone. It is a clear oily solution for intramuscular injection. Each mL contains 100 mg methenolone enanthate, with benzyl alcohol (1.5% v/v) as preservative, ethyl oleate, and ricinus oil (castor oil) as carrier oils. Half-life: Approximately 10 days.
**12 CLINICAL PHARMACOLOGY**
**12.1 Mechanism of Action**
Methenolone enanthate binds to androgen receptors, promoting protein synthesis and nitrogen retention with minimal androgenic effects, ideal for lean muscle preservation and fat loss.
**12.3 Pharmacokinetics**
Absorbed slowly after intramuscular injection; peak plasma levels in 2-3 days; half-life approximately 10 days. Metabolized in the liver; excreted primarily in urine.
**13 NONCLINICAL TOXICOLOGY**
Animal studies indicate potential carcinogenicity, including hepatic tumors; no human data available. Use caution due to androgenic effects.
**16 HOW SUPPLIED/STORAGE AND HANDLING**
10 mL multi-dose vial, 100 mg/mL. Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). Protect from light. Keep out of reach of children.
*Manufactured by: Medi Pharma*
